
Significant progress has been made in the development and application of targeted therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, for the treatment of lung cancer, offering new hope for improved patient outcomes.


coremsg

Drs Xiuning Le, Sandip Patel, and Yi-Long Wu discuss exciting data reported out for targeted therapy, especially in lung cancer space, at ASCO 2024.

ASCO 2024: Advances in Targeted Therapy for Lung Cancer

groundbreaking-advances-in-targeted-therapies-for-lung-cancer-unveiled-at-asco-2024


Groundbreaking Advances in Targeted Therapies for Lung Cancer Unveiled at ASCO 2024
